| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Endocrinology and Metabolism (J.M., N.U., H.L.), Pharmacology and Toxicology (St.S., V.H.), Obstetrics and Gynecology (So.S.), and Nuclear Medicine (J.M., R.S.), Otto-von-Guericke-University, D-39120 Magdeburg, Germany
Address all correspondence and requests for reprints to: Prof. Dr. Hendrik Lehnert Department of Endocrinology and Metabolism University Hospital of Magdeburg Leipziger Strasse 44, D-39120 Magdeburg, Germany. E-mail: hendrik.lehnert{at}medizin.uni-magdeburg.de.
The stable somatostatin analog octreotide has been successfully used for imaging and treatment of a variety of human tumors. In pheochromocytoma, data on somatostatin receptor subtyping have thus far been sparse. Pheochromocytomas often express more than one somatostatin receptor, and it is uncertain by which receptor subtype the functional responses of octreotide are mediated. Here, we have examined somatostatin receptor protein expression in a panel of 52 pheochromocytomas from 35 randomly selected patients by immunostaining with specific polyclonal anti-sst1–5 and monoclonal mouse anti-SS-14 antibodies. Staining pattern, distribution and subcellular localization of somatostatin receptor subtypes were investigated. Seventeen patients received 111In-octreotide scintigraphy. Although the vast majority of tumors (90%) showed positive immunohistochemical staining for sst3, immunoreactive sst2A receptors were only seen in 13 tumors (25%). All other somatostatin receptor subtypes were less frequently detected. Interestingly, among sst3-positive tumors strikingly different subcellular distributions of immunoreactive sst3 receptors were observed. In most cases, immunoreactive sst3 receptors were distributed throughout the cytosol. Scintigraphic localization of tumors larger than 1 cm in diameter was always successful in the presence of immunoreactive sst2A receptors. In the absence of sst2A, true-positive octreotide scintigraphy was only seen in the presence of membrane-associated sst3 immunoreactivity. Our findings suggest that selective expression of functional membrane-associated sst3 receptors is sufficient for high tracer uptake during octreotide scintigraphy in a subgroup of human pheochromocytomas. These tumors may represent a potential target treatment with somatostatin receptor agonists with improved sst3 activity.
This work was supported by Deutsche Forschungsgemeinschaft Grants SCHU 1332/2-1 (So.S.) and SCHU 924/4–3 (St.S.).
J.M. and N.U. contributed equally to this work.
Abbreviations: DAB, Diaminobenzidine; HEK, human embryonic kidney; MIBG, metaiodobenzylguanidine; RT, room temperature.
This article has been cited by other articles:
 |
|
 |
|
  T. Fischer, C. Doll, S. Jacobs, A. Kolodziej, R. Stumm, and S. Schulz Reassessment of sst2 Somatostatin Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-1 J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4519 - 4524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pasquali, V. Rossi, G. Conzo, G. Pannone, P. Bufo, A. De Bellis, A. Renzullo, G. Bellastella, A. Colao, G. Vallone, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells J. Mol. Endocrinol., June 1, 2008; 40(6): 263 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Asnacios, F. Courbon, P. Rochaix, E. Bauvin, V. Cances-Lauwers, C. Susini, S. Schulz, A. Boneu, R. Guimbaud, and L. Buscail Indium-111-Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors J. Clin. Oncol., February 20, 2008; 26(6): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ben-Shlomo, O. Pichurin, N. J. Barshop, K. A. Wawrowsky, J. Taylor, M. D. Culler, V. Chesnokova, N.-A. Liu, and S. Melmed Selective Regulation of Somatostatin Receptor Subtype Signaling: Evidence for Constitutive Receptor Activation Mol. Endocrinol., October 1, 2007; 21(10): 2565 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert Current Treatment of Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ginj, H. Zhang, B. Waser, R. Cescato, D. Wild, X. Wang, J. Erchegyi, J. Rivier, H. R. Macke, and J. C. Reubi Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors PNAS, October 31, 2006; 103(44): 16436 - 16441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulz, C. Rocken, M. P A Ebert, and S. Schulz Immunocytochemical identification of low-affinity NTS2 neurotensin receptors in parietal cells of human gastric mucosa. J. Endocrinol., October 1, 2006; 191(1): 121 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulz, R. Stumm, C. Rocken, C. Mawrin, and S. Schulz Immunolocalization of Full-length NK1 Tachykinin Receptors in Human Tumors J. Histochem. Cytochem., September 1, 2006; 54(9): 1015 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bodei, G. Paganelli, and G. Mariani Receptor Radionuclide Therapy of Tumors: A Road from Basic Research to Clinical Applications J. Nucl. Med., March 1, 2006; 47(3): 375 - 377. [Full Text] [PDF]
|
|
|
|
|
|
S. Schulz, C. Rocken, C. Mawrin, and S. Schulz Immunohistochemical Localization of CCK1 Cholecystokinin Receptors in Normal and Neoplastic Human Tissues J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6149 - 6155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vezzosi, A. Bennet, P. Rochaix, F. Courbon, J. Selves, B. Pradere, L. Buscail, C. Susini, and P. Caron Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies Eur. J. Endocrinol., May 1, 2005; 152(5): 757 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulz, C. Rocken, C. Mawrin, W. Weise, V. Hollt, and S. Schulz Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies Clin. Cancer Res., December 15, 2004; 10(24): 8235 - 8242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Eisenhofer, S. R Bornstein, F. M Brouwers, N.-K. V Cheung, P. L Dahia, R. R de Krijger, T. J Giordano, L. A Greene, D. S Goldstein, H. Lehnert, et al. Malignant pheochromocytoma: current status and initiatives for future progress Endocr. Relat. Cancer, September 1, 2004; 11(3): 423 - 436. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
